Symbicort Turbohaler (formoterol budesonide): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Symbicort Turbohaler 100/6, Inhalation powder.

Symbicort Turbohaler is indicated in adults, adolescents, and children aged 6 years and older.

Symbicort Turbohaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.

or

- patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Note: Symbicort Turbohaler (100 micrograms/6 micrograms/inhalation) is not appropriate in patients with severe asthma.

Symbicort Turbohaler 200/6 Inhalation powder

Asthma

Symbicort Turbohaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.

or

- patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Symbicort Turbohaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).

Symbicort Turbohaler 400/12, Inhalation powder.

Asthma

Symbicort Turbohaler is indicated in adults, and adolescents aged 12 - 17 years, for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.

or

- patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Symbicort Turbohaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4).


Route of administration: opinion.traitement.inhalation
Molecule: formoterol, budesonide

Patients' opinions on Symbicort Turbohaler

In brief

General satisfaction level: 8.00/10 Learn more

Treatment's effectiveness: 8.33/10 Learn more

Ease of use: 8.33/10 Learn more

Adherence to prescription: 8.67/10 Learn more

Detected side effects: 1.67/10 Learn more

Improvement in the quality of life: 6.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
Maggie-mae
on 21/08/2018

Easy to use, indicator along the side shows when your running out

Your message

Members using this Symbicort Turbohaler

Conditions related to this medication

Fact sheet

Asthma

See the fact sheet
Fact sheet

COPD

See the fact sheet